『MEDCast』のカバーアート

MEDCast

MEDCast

著者： MJH Life Sciences
無料で聴く

このコンテンツについて

 MEDCast is a healthcare program brought to you by HCPLive.com that features leading medical experts who discuss a range topic within a particular condition or medical disorder.© 博物学 生物科学 科学 自然・生態学 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Empowering Pharmacists in the Management of Patients With Urothelial Cancer

    Empowering Pharmacists in the Management of Patients With Urothelial Cancer
    2025/09/03
    Sherry Vogt, PharmD, BCOP; and Megan Hinkley, PharmD, MBA, BCOP, discuss how pharmacists play a crucial role in managing patients with bladder cancer through treatment selection, patient education, adverse effect monitoring, and the evolving landscape of therapies including traditional chemotherapy, immunotherapy, and antibody-drug conjugates like enfortumab vedotin plus pembrolizumab.
    続きを読む 一部表示
    46 分
  • Personalizing Progress: New Data Shaping Care in Central Precocious Puberty

    Personalizing Progress: New Data Shaping Care in Central Precocious Puberty
    2025/08/29
    Panelists discuss how central precocious puberty involves early activation of the hypothalamic-pituitary-gonadal axis before age 8 in girls and age 9 in boys, requiring individualized treatment decisions based on factors like growth velocity, bone age advancement, and psychosocial impact, with GnRH agonist therapies available in multiple formulations (injections and implants) that effectively suppress puberty while preserving final height potential and having reassuring long-term safety profiles for bone health and fertility outcomes.
    続きを読む 一部表示
    43 分
  • Empowering Pharmacists in the Management of Patients With Urothelial Cancer

    Empowering Pharmacists in the Management of Patients With Urothelial Cancer
    2025/08/27
    Sherry Vogt, PharmD, BCOP; and Megan Hinkley, PharmD, MBA, BCOP, discuss how pharmacists play a crucial role in managing patients with bladder cancer through treatment selection, patient education, adverse effect monitoring, and the evolving landscape of therapies including traditional chemotherapy, immunotherapy, and antibody-drug conjugates like enfortumab vedotin plus pembrolizumab.
    続きを読む 一部表示
    47 分
まだレビューはありません